Arup Bhattacharya

Arup Bhattacharya

PhD

Special Interests:

Anticancer effects of antinagiogenic methylselenocysteine (MSC) in combination therapy using different human cancer xenografts including colorectal, head & neck and lung cancer Isothiocyanate (ITC) and ITC containing natural substances such as Mustard, Broccoli, Wasabi and Horseradish in retarding bladder cancer growth, progression and invasion in vivo Anticancer efficacy of homeopathic remedies in vivo
About Me

Biography:

Dr. Arup Bhattacharya joined the PhD program in Cellular and Molecular Biophysics in the Roswell Park Graduate Division, SUNY at Buffalo in 1999. After completing his PhD in 2005, he did his postdoctoral training in Translational Pharmacology and Physiology under Dr Youcef M. Rustum in the Department of Cancer Biology. His postdoctoral training was supported partly by a postdoctoral grant from American Institute for Cancer Research. Since 2009 he is an Affiliate member in the Department of Cancer Prevention and Control.

Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Affiliate Member
  • Department of Chemoprevention
State University of New York at Buffalo
  • Associate Research Professor
  • Department of Natural Sciences
  • Roswell Park Graduate Division

Background

Education and Training:

  • PhD (Molecular & Cellular Biophysics) State University of NY at Buffalo, NY

Professional Memberships:

  • American Association for Cancer Research
  • American Association of Physicists in Medicine
  • International Society for Magnetic Resonance in Medicine
  • Homeopathic Medical Council of Canada
  • North American Society of Homeopaths
  • National United Professional Association of Trained Homeopaths
Research

Research Overview:

The role of MSC as a therapeutic agent in augmenting chemotherapeutic efficacy in combination chemotherapy is being investigated in terms of a common underlying factors. The relevance of histomorphology and tumor cell differentiation on the therapeutic efficacy is being pursued for determining clinic relevance. This study is currently being supported by an NCI grant.

Bladder cancer is one of the most expensive cancers to treat due to repeated recurrence and in the clinic it leads to higher mortality when it invades the bladder wall. Using in vivo preclinical bladder cancer model, the antitumor activity of various ITCs and ITC containing natural substances is being pursued. 

Homeopathy has remained in the fringe due to paucity of studies in basic science. There has recently been validated report of its possible efficacy in some cancers. Research is being pursued to check the feasibility in vivo of using some homeopathic remedies for its possible anticancer efficacy.

Three components of Dr. Arup’s research are:

  1. Anticancer effects of dietary supplement selenium especially focusing on the organoselenium compound methylselenocysteine for its unique properties including a low toxicity profile in vivo. The effect on HIF-1α, VEGF, iNOS, Cox-2 is being studied in order to understand the antiangiogenic efficacy of MSC in vivo.
  2. The anticancer role of isothiocyanate (ITCs) and ITC containing natural products in retarding bladder cancer growth, progression and invasion.
  3. Possible anticancer efficacy of some homeopathic remedies in vivo.

Publications

Bhattacharya A, Tang L, Li Y, Geng F, Paonessa JD, Chen SC, Wong MKK, Zhang Y. Inhibition of bladder cancer development by allyl isothiocyanate.Carcinogenesis 2010; 31(2):281-286

Rustum YM, T�th K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison CD, Cao S, Bhattacharya A. Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. Journal of oncology2010; 2010 :396286

. Towards a better understanding of health and disease.  In A compendium of essays on alternative therapy, <[[edition]]>; <[[city]]>: InTech, 2012; 111-122.

Chintala S, Slocum HK, Dean R, Zinia TR, Durrani FA, Cao S, Ola MS, Smith SB, Bhattacharya A, Yin M-B, T�th K, Rustum YM. Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.Chemotherapy 2010; 56(3):223-233

Bhattacharya A , Li Y , Wade KL , Paonessa JD , Fahey JW , Zhang Y. Allyl isothiocyanate-rich mustard seed powder inhibits bladder cancer growth and muscle invasion. Carcinogenesis 2010; 31(12):2105-2110

Bhattacharya A, Toth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky EA, Rustum YM. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clinical colorectal cancer 2009;8(3):155-162

Bhattacharya A , Turowski SG , Martin ID , Rajput A , Rustum YM , Hoffman RM , Seshadri M. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer research 2011; 31(2):387-393

Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert opinion on drug delivery 2011; 8(6):749-763

Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, Rustum YM.Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.Clinical cancer research 2008; 14(12):3926-3932

Bhattacharya A, Toth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. Neoplasia (New York, N.Y.) 2008; 10(8):857-865

Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM.Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation. Cancer letters 2011; 311(2):219-229

Bhattacharya A, Toth K, Cao SS, Azrak RG, Durrani FA, Rustum YM, Pendyala L. Se-(methyl)selenocysteine causes tumor vessel maturation leading to synergistic antitumor effect in human xenografts. Journal of nutrition 2007;137(1 Suppl.):278S

Cao S, Durrani FA, Bhattacharya A, Yu Y, Rustum YM. Enhanced irinotecan toxicity in UDPGT deficient GUNN rats: Role of UDPGT1A in irinotecan detoxification. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:1139

Seshadri M, Bhattacharya A, Toth K, Rustum YM. Contrast-enhanced MR1 of the vascular response of human tumor xenografts to the chemopreventive agent selenium in vivo: Implications for combination therapy. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:119

Bhattacharya A, Li Y, Geng F, Munday R, Zhang Y. The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis2012; 33(2):394-398

Bhattacharya A, Turowski SG, San Martin ID, Rajput A, Rustum YM, Hoffman RM, Seshadri M. Combined magnetic resonance and fluorescence-protein imaging to simultaneously assess the anti-tumor and anti-angiogenesis efficacy of selenium. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #4284